Phenytoin half-life and clearance during maintenance therapy in adults and elderly patients with epilepsy

Neurology

Volumn 71, Issue 1, 2008, Pages 38-43

  Ahn, J E ^a,e   Cloyd, J C ^a,b   Brundage, R C ^a   Marino, S E ^a   Conway, J M ^a   Ramsay, R E ^c   White, J R ^d   Musib, L C ^a,f   Rarick, J O ^a   Birnbaum, A K ^a   Leppik, I E ^a,b,d  

^a Department of Pharmaceutical Sciences College of Pharmacy   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d MINCEP Epilepsy Care   (United States)

^e Development Solutions   (United States)

^f ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(2 CARBON 13 1,3 NITROGEN 15) 5,5 DIPHENYLHYDANTOIN SODIUM SALT; (2,4,5 CARBON 13 1,3 NITROGEN 15) 5,5 DIPHENYL 3 (PHOSPHOXYMETHYL) 2,4 IMIDAZOLIDINEDIONE DISODIUM SALT; FOSPHENYTOIN SODIUM; PHENYTOIN DERIVATIVE; STABLE ISOTOPE; UNCLASSIFIED DRUG; ANTICONVULSIVE AGENT; PHENYTOIN;

ADULT; AGE; AGED; ARTICLE; BLOOD SAMPLING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; EPILEPSY; FEMALE; GENDER; HUMAN; ISOTOPE LABELING; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MASS FRAGMENTOGRAPHY; MORNING DOSAGE; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT OUTCOME; AGING; BLOOD; DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; SEX DIFFERENCE;

ADMINISTRATION, ORAL; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ANTICONVULSANTS; DRUG ADMINISTRATION SCHEDULE; EPILEPSY; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PHENYTOIN; SEX FACTORS;

EID: 48249098927     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000316392.55784.57     Document Type: Article

References (40)

1. Cusack BJ. Pharmacokinetics in older persons. Am J Geri-atr Pharmacother 2004;2:274-302.
2. Garrard J, Cloyd J, Gross C, et al. Factors associated with antiepileptic drug use among elderly nursing home residents. J Gerontol A Biol Sci Med Sci 2000;55:M384-392.
3. Berlowitz DR, Pugh MJ. Pharmacoepidemiology in community-dwelling elderly taking antiepileptic drugs. Int Rev Neurobiol 2007;81:153-163.
4. Thummel K, Shen D. Design and optimization of dosage regimens: pharmacokinetic data. Appendix II. In: Hard-man JG LL, ed. Goodman and Gilman's The Pharmacological Basis for Therapeutics, 10th ed. New York: McGraw-Hill, 2001: 1995.
5. Bachmann KA, Belloto RJ, Jr. Differential kinetics of phe-nytoin in elderly patients. Drugs Aging 1999;15:235-250.
6. Bauer LA, Blouin RA. Age and phenytoin kinetics in adult epileptics. Clin Pharmacol Ther 1982;31:301-304.
7. Hayes MJ, Langman MJ, Short AH. Changes in drug metabolism with increasing age: 2: phenytoin clearance and protein binding. Br J Clin Pharmacol 1975;2:73-79.
8. Houghton GW, Richens A, Leighton M. Effect of age, height, weight and sex on serum phenytoin concentration in epileptic patients. Br J Clin Pharmacol 1975;2:251-256.
9. Lambie DG, Johnson RH, Nanda RN, Shakir RA. Therapeutic and pharmacokinetic effects of increasing phenytoin in chronic epileptics on multiple drug therapy. Lancet 1976;2:386-389.
10. Valodia P, Seymour MA, Miller R, McFadyen ML, Folb PI. Factors influencing the population pharmacokinetic parameters of phenytoin in adult epileptic patients in South Africa. Ther Drug Monit 1999;21:57-62.
11. Browne TR. Stable isotopes in clinical pharmacokinetic investigations. Advantages and disadvantages. Clin Phar-macokinet 1990;18:423-433.
12. Levy RH, Collins C. Risk and predictability of drug interactions in the elderly. Int Rev Neurobiol 2007;81:235-251.
13. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003;2:347-356.
14. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003;2:473-481.
15. Nelson MH, Birnbaum AK, Nyhus PJ, Remmel RP. A capillary GC-MS method for analysis of phenytoin and [13C3]-phenytoin from plasma obtained from pulse dose pharmacokinetic studies. J Pharm Biomed Anal 1998;17: 1311-1323.
16. Gibaldi M. Pharmacokinetics, 2nd ed. New York: Marcel Dekker, Inc., 1982.
17. Browne TR, Van Langenhove A, Costello CE, Biemann K, Greenblatt DJ. Kinetic equivalence of stable-isotope-labeled and unlabeled phenytoin. Clin Pharmacol Ther 1981;29:511-515.
18. Kasuya Y, Mamada K, Baba S, Matsukura M. Stable-isotope methodology for the bioavailability study of phe-nytoin during multiple-dosing regimens. J Pharm Sci 1985;74:503-507.
19. Bach B, Hansen JM, Kampmann JP, Rasmussen SN, Sk-ovsted L. Disposition of antipyrine and phenytoin correlated with age and liver volume in man. Clin Pharmacokinet 1981;6:389-396.
20. Battino D, Croci D, Mamoli D, Messina S, Perucca E. Influence of aging on serum phenytoin concentrations: a pharmacokinetic analysis based on therapeutic drug monitoring data. Epilepsy Res 2004;59:155-165.
21. Hudson SA, Farquhar DL, Thompson D, Smith RG. Phe-nytoin dosage individualization - five methods compared in the elderly. J Clin Pharm Ther 1990;15:25-34.
22. Grasela TH, Sheiner LB, Rambeck B, et al. Steady-state pharmacokinetics of phenytoin from routinely collected patient data. Clin Pharmacokinet 1983;8:355-364.
23. Sherwin AL, Loynd JS, Bock GW, Sokolowski CD. Effects of age, sex, obesity, and pregnancy on plasma diphenylhy-dantoin levels. Epilepsia 1974;15:507-521.
24. Frame B, Beal SL. Non-steady state population kinetics of intravenous phenytoin. Ther Drug Monit 1998;20:408-416.
25. Jung D, Powell JR, Walson P, Perrier D. Effect of dose on phenytoin absorption. Clin Pharmacol Ther 1980;28: 479-485.
26. Browne TR, Leduc B. Phenytoin and other hydantoins: chemistry and biotransformation. In: Levy RH MR, Mel-drum BS, Perucca E, ed. Antiepileptic Drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2002:565-580.
27. Richens A. A study of the pharmacokinetics of phenytoin (diphenylhydantoin) in epileptic patients, and the development of a nomogram for making dose increments. Epi-lepsia 1975;16:627-646.
28. Gugler R, Manion CV, Azarnoff DL. Phenytoin: pharma-cokinetics and bioavailability. Clin Pharmacol Ther 1976; 19:135-142.
29. Strandjord RE, Johannessen SI. One daily dose of diphe-nylhydantoin (DPH) to patients with epilepsy. Acta Neu-rol Scand Suppl 1972;51:499-500.
30. Lund L, Alvan G, Berlin A, Alexanderson B. Pharmacoki-netics of single and multiple doses of phenytoin in man. Eur J Clin Pharmacol 1974;7:81-86.
31. Arnold K, Gerber N. The rate of decline of diphenylhy-dantoin in human plasma. Clin Pharmacol Ther 1970;11: 121-134.
32. Browne TR, Szabo GK, Schumacher GE, Greenblatt DJ, Evans JE, Evans BA. Bioavailability studies of drugs with nonlinear pharmacokinetics: I: tracer dose AUC varies directly with serum concentration. J Clin Pharmacol 1992; 32:1141-1145.
33. Browne TR, Evans JE, Szabo GK, Evans BA, Greenblatt DJ, Schumacher GE. Studies with stable isotopes I: changes in phenytoin pharmacokinetics and biotransfor-mation during monotherapy. J Clin Pharmacol 1985;25: 43-50.
34. Bernus I, Dickinson RG, Hooper WD, Eadie MJ. Anti-convulsant therapy in aged patients. Clinical pharmacoki-netic considerations. Drugs Aging 1997;10:278-289.
35. Arroyo S, Kramer G. Treating epilepsy in the elderly: safety considerations. Drug Saf 2001;24:991-1015.
36. Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy: a randomized study of gabapentin, lam-otrigine, and carbamazepine. Neurology 2005;64:1868-1873.
37. Albrecht S, Ihmsen H, Hering W, et al. The effect of age on the pharmacokinetics and pharmacodynamics of mida-zolam. Clin Pharmacol Ther 1999;65:630-639.
38. Pan HY, Hoffman BB, Pershe RA, Blaschke TF. Decline in beta adrenergic receptor-mediated vascular relaxation with aging in man. J Pharmacol Exp Ther 1986;239:802-807.
39. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouel-lette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989;261:3273-3277.
40. Leppik IE. Introduction to the International Geriatric Epilepsy Symposium (IGES). Epilepsy Res 2006;68 suppl 1:S1-4.